The Non-Malignant Channel is supported with funding from Agios (Gold).
The Sickle Cell Disease Channel is supported with funding from Agios (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCAT 2024 | The importance of basic science research in hemoglobinopathies
Sara El Hoss, PhD, Imagine Institute of Genetic Diseases, Paris, France, emphasizes the critical role of basic science research in understanding the pathophysiology of diseases, including sickle cell disease (SCD), highlighting how such research has paved the way for novel therapies, including curative cellular-based treatments like gene therapy. This interview took place at the 19th Annual Scientific Conference of the Academy for Sickle Cell and Thalassaemia (ASCAT 2024) in London, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
